Brief: Glycomimetics Reports Highlights And Financial Results For First Quarter 2023
03/05/2023 12:38
GlycoMimetics Inc GLYC.O :
* GLYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR
FIRST
QUARTER 2023
* GLYCOMIMETICS INC - CASH AND CASH EQUIVALENTS EXPECTED TO
FUND
CURRENT OPERATIONS INTO LATE 4TH QUARTER OF 2024
* GLYCOMIMETICS INC QTRLY NET LOSS PER SHARE - BASIC AND
DILUTED
$0.17
Source text for Eikon: ID:nBw344L8Na
Further company coverage: GLYC.O
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering